Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis

E Glyn V Evans, Bárður Sigurgeirsson for the LION study group

Abstract

Objective To compare the efficacy and safety of continuous terbinafine with intermittent itraconazole in the treatment of toenail onychomycosis.

Design Prospective, randomised, double blind, double dummy, multicentre, parallel group study lasting 72 weeks.

Setting 35 centres in six European countries.

Subjects 496 patients aged 18 to 75 years with a clinical and mycological diagnosis of dermatophyte onychomycosis of the toenail.

Interventions Study patients were randomly divided into four parallel groups to receive either terbinafine 250 mg a day for 12 or 16 weeks (groups T₁₂ and T₁₆) or itraconazole 400 mg a day for 1 week in every 4 weeks for 12 or 16 weeks (groups I₃ and I₄).

Main outcome measures Assessment of primary efficacy at week 72 was mycological cure, defined as negative results on microscopy and culture of samples from the target toenail.

Results At week 72 the mycological cure rates were 75.7% (81/107) in the T₁₂ group and 80.8% (80/99) in the T₁₆ group compared with 38.3% (41/107) in the I₃ group and 49.1% (53/108) in the I₄ group. All comparisons (T₁₂ v I₃, T₁₂ v I₄, T₁₆ v I₃, T₁₆ v I₄) showed significantly higher cure rates in the terbinafine groups (all P < 0.0001). Also, all secondary clinical outcome measures were significantly in favour of terbinafine at week 72. There were no differences in the number or type of adverse events recorded in the terbinafine or itraconazole groups.

Conclusion Continuous terbinafine is significantly more effective than intermittent itraconazole in the treatment of patients with toenail onychomycosis.

Introduction

With a prevalence among adults of 2-4%¹⁻⁴ onychomycosis is one of the most common nail diseases and one of the few that are curable, providing it is diagnosed correctly. Systemic treatments for onychomycosis now include terbinafine, an allylamine that is primarily fungicidal, and itraconazole, a triazole that is primarily fungistatic; both represent a major therapeutic advance over griseofulvin in the treatment of this condition. For toenail infections terbinafine is usually

taken continuously for 12 weeks, whereas itraconazole is taken either continuously for the same period or intermittently—that is, 1 week in 4 weeks for 12 or 16 weeks.

Two double blind studies which compared the efficacy of continuous treatment with terbinafine and itraconazole in onychomycosis have both shown terbinafine to be significantly superior.^{5,6} Because therapeutic concentrations of itraconazole are believed to persist in the nail for a considerable time after systemic treatment is stopped, intermittent therapy—with higher daily doses to achieve and maintain therapeutic concentrations—might be an effective alternative to continuous treatment. Such intermittent treatment is widely used currently to treat onychomycosis and is claimed to be as effective for this indication as both continuous itraconazole and continuous terbinafine.^{7,8}

Few direct comparisons of continuous terbinafine versus intermittent itraconazole for onychomycosis exist and those that do are relatively small open studies.⁹ We conducted the first large scale, double blind comparison of continuous terbinafine with intermittent itraconazole in the treatment of toenail onychomycosis.

Methods

Protocol

Study outline—We undertook a prospective, randomised, double blind, double dummy, multicentre, parallel group study over 72 weeks. A total of 38 investigators from 35 centres in six European countries (Finland, Germany, Iceland, Italy, the Netherlands, and the United Kingdom) participated in the study, the objective of which was to compare the efficacy and safety of continuous terbinafine with intermittent itraconazole in the treatment of toenail onychomycosis.

Inclusion criteria—Participants were men and women aged 18 to 75 years with a clinical diagnosis of onychomycosis of the toenail (distal subungual or total dystrophic) confirmed by positive results on mycological culture and microscopy (examination in potassium hydroxide (KOH)). Only patients with dermatophyte infections were included, and all were required to have an affected great toenail (target nail) capable of

Public Health
Laboratory Service
(PHLS) Mycology
Reference
Laboratory,
University of Leeds
and General
Infirmary, Leeds
LS2 9JT
E Glyn V Evans,
professor of medical
mycology

University of
Iceland and
Reykjavik City
Hospital, Reykjavik,
Iceland
Bárður
Sigurgeirsson,
assistant professor of
dermatology

Correspondence to:
Professor Evans
E.G.V.Evans@
leeds.ac.uk

BMJ 1999;318:1031-5

regrowth. Involvement of the great toenail usually occurs in cases that are difficult to treat.

Exclusion criteria—The main exclusion criteria included the use of systemic antifungal treatment in the previous 12 months or topical antifungal treatment within 4 weeks before screening; use of drugs known or believed to interact with either of the study agents; people with conditions that might result in altered absorption, metabolism, or excretion of the study drugs; or radiotherapy, chemotherapy, or immunosuppressive therapy within 12 weeks before the beginning of the study. Other exclusion criteria were pregnancy or lactation; no use of contraception in women of childbearing age; psoriasis, mucocutaneous candidiasis, or immunodeficiency; and alanine transaminase or aspartate transaminase concentrations, or both, more than 1.5 times above the upper limit of the normal range or serum creatinine concentration above 300 $\mu\text{mol/L}$.

Planned interventions—Patients were randomly allocated to one of four groups: terbinafine 250 mg a day for 12 weeks (T_{12}) or 16 weeks (T_{16}) or itraconazole 400 mg (four capsules of 100 mg) a day taken for 1 week in every 4 weeks for either 12 weeks (I_3) or 16 weeks (I_4). The double dummy system used to blind the study treatments involved the use of placebo tablets and placebo capsules to ensure that all patients took one tablet a day for 16 weeks and four capsules a day for weeks 1, 5, 9, and 13. To facilitate absorption of itraconazole all study medication was taken with meals. Patients were assessed at weeks 4, 8, 12 (end of active treatment for groups T_{12} and I_3) and 16 (end of active treatment for groups T_{16} and I_4) and then followed up with blinded assessments at weeks 24, 36, 48, and 72. Patients were regarded as non-compliant if they failed to take more than two complete daily doses of study medication in any 1 week or more than seven doses in any 1 month; these patients did not continue in the study.

Mycology—All mycological examinations were undertaken at a single laboratory (Public Health Laboratory Service (PHLS) Mycology Reference Laboratory, Leeds).

Ethics—The study protocol conformed to good clinical practice for trials on medicinal products in the European Community; the United States code of federal regulations dealing with clinical studies; and the Declaration of Helsinki on medical research in humans. All patients gave written informed consent to participation in the study and the study protocol was subject to approval by the institutional review board at each study centre.

Primary and secondary outcome measures—The primary efficacy parameter was mycological cure, defined as negative results on microscopy and negative results on fungal culture of samples taken from the target toenail. Rates of mycological cure were assessed at week 72. Secondary efficacy criteria included clinical cure (100% toenail clearing), complete cure (mycological and clinical cure), clinical effectiveness (mycological cure and at least 5 mm of new clear toenail growth), and global assessments by physician and patient. Global assessments were performed from weeks 12 to 72, with both physician and patient basing their assessments on the perceived condition of all affected toenails. The scale used included ratings of very good

or excellent (none or minimal signs and symptoms); good (considerable improvement); fair (slight improvement); and poor (no change or worse).

Rationale and methods for statistical analysis—The study was designed to include at least 480 patients (120 in each group). Based on the assumption of a 70% mycological cure rate with itraconazole the study had 80% power to detect a 15% difference at the 5% level of significance. Treatment comparisons for cure rates (mycological, clinical, complete, and clinical effectiveness) and global assessments were analysed by the Cochran-Mantel-Haenszel test adjusted for country. Results for all efficacy assessments were based on the observed patients of the intention to treat population. Analyses were also performed with the "last observation carried forward" method.

Assignment

Treatment was assigned according to a predetermined computer generated randomisation code produced by Novartis. Thus study treatments (groups T_{12} , T_{16} , I_3 , I_4) were randomly allotted to sequential patient numbers in balanced blocks of four by centre and investigators then allocated patient numbers sequentially at baseline.

Blinding

Details of blinding are summarised in table 1. All patients took one tablet a day for weeks 1 to 16, either active (terbinafine 250 mg) or placebo. All patients also took two capsules twice daily (total of four capsules daily), either active (itraconazole 100 mg) or placebo, for weeks 1, 5, 9, and 13. All placebo tablets and capsules were identical in taste and appearance to the respective active compounds. The randomisation code was stored with Novartis and nobody involved in the conduct of the study had access to the code until the database was complete and locked.

Results

Participant flow and follow up

A total of 843 patients were screened (figure 1) but 336 of these were excluded because of negative results on fungal culture, withdrawal of consent, protocol violations, or failure to return to the clinic. The 507 remaining patients were randomised for treatment, of whom 506 constituted the study population and 496 the intention to treat population (the 10 patients excluded

Table 1 Details of treatment allocation and blinding. All tablets or capsules given daily

Treatment group and weeks	Tablets/capsules received
T_{12}	
1-12	1 terbinafine (250 mg)
13-16	1 placebo tablet
1, 5, 9, 13	4 placebo capsules
T_{16}	
1-16	1 terbinafine (250 mg)
1, 5, 9, 13	4 placebo capsules
I_3	
1-16	1 placebo tablet
1, 5, 9	4 itraconazole (100 mg)
13	4 placebo capsules
I_4	
1-16	1 placebo tablet
1, 5, 9, 13	4 itraconazole (100 mg)

Fig 1 Distribution of participants in study, showing randomisation of intention to treat population between four treatment groups and number of patients remaining in each group at weeks 48 and 72. T₁₂ and T₁₆ indicate allocation to terbinafine for 12 or 16 weeks. I₃ and I₄ indicate allocation to itraconazole for 1 week a month for 3 or 4 months. Patients not randomised (n=336) because of negative results on microscopy or fungal culture, or both, at baseline (n=263); protocol violation (n=19); withdrawal of consent (n=18); or other (n=36). Reasons for the 87 withdrawals (for T₁₂, T₁₆, I₃, and I₄, respectively) were adverse events (8, 13, 5, 8); withdrawal of consent (2, 1, 3, 2); protocol violation (0, 2, 2, 5); treatment failure (0, 0, 8, 6); failure to return (4, 4, 4, 4); and other (0, 3, 3, 0)

violated the inclusion or exclusion criteria but had received at least one dose of medication). There were no significant differences at baseline between the four treatment groups with regard to demographics or to the extent and duration of nail disease (table 2).²

Analysis

Causal agents—The species of dermatophyte isolated at screening were *Trichophyton rubrum* (443; 89.3%), *T rubrum* plus a non-dermatophyte mould (8; 1.6%), *T rubrum* plus *T mentagrophytes* (3; 0.6%), or *T mentagrophytes* alone (42; 8.5%). Also, of all the patients

screened for whom a fungus was cultured, dermatophytes were encountered in 95.7% (555/580).

Effects of interventions—Results for all assessments of efficacy for the primary and secondary outcome measures are based on intention to treat. Analyses were also performed with the “last observation carried forward” method. Results did not change with this method nor were there any differences in results when the two populations were analysed separately. Mean compliance was over 99% in all treatment groups.

Cure rates

Table 3 and figure 2 summarise the overall cure rates. Differences in mycological cure significantly favoured terbinafine in all comparisons ($P < 0.0001$), and all comparisons for clinical cure showed significant superiority of both terbinafine regimens versus either of the intermittent itraconazole regimens ($P \leq 0.0022$). As with the mycological cure rates the clinical cure rates for the continuous terbinafine groups continued to increase after treatment through to week 72. This was not the case for the intermittent itraconazole groups. All comparisons also showed significantly higher rates of complete cure in the continuous terbinafine groups compared with both the itraconazole regimens ($P \leq 0.0044$). For clinical effectiveness and global assessments all comparisons showed significantly higher rates of cure for the continuous terbinafine groups ($P < 0.0001$).

Safety

A total of 236 patients reported at least one adverse event (55 for T₁₂, 61 for T₁₆, 60 for I₃, and 60 for I₄). All were within the known safety profile of both drugs, and there were no significant differences in adverse events between the four treatment regimens. The most commonly reported adverse events were nausea, headache, upper respiratory tract infection, chest infection, back pain, flu-like symptoms, bronchitis, and fever, although most were considered by the investigators to be mild or moderate and unrelated to the study medications.

Discussion

We have shown in this study that terbinafine 250 mg a day over 12 or 16 weeks produces better mycological and clinical cure rates at week 72 than intermittent itraconazole given over the same periods. Rates of

Table 2 Baseline demographics of patients enrolled in study according to treatment for toenail onychomycosis

Parameter	Terbinafine 12 weeks	Terbinafine 16 weeks	Itraconazole 3 cycles	Itraconazole 4 cycles	All patients	Overall P value
No of patients	124	120	126	126	496	
Mean (SD) age (years)	50.1 (12.3)	50.9 (13.1)	50.7 (12.6)	48.6 (13.1)	50.1 (12.8)	0.4549
Proportion (%) of women	42.7	43.3	42.9	38.9	41.9	0.8637
Race (% white; % Asian/Oriental)	97.6; 2.4	99.2; 0.8	99.2; 0.8	98.4; 1.6	98.6; 1.4	0.736
Dermatophytes (%):						
<i>T rubrum</i>	91.9	85.8	88.9	90.5	89.3	0.3549
<i>T rubrum</i> plus non-dermatophyte mould	1.6	2.5	1.6	0.8	1.6	
<i>T rubrum</i> plus <i>T mentagrophytes</i>				2.4	0.6	
<i>T mentagrophytes</i>	6.5	11.7	9.5	6.3	8.5	
Mean (SD) No of infected toenails	5.6 (2.8)	6 (2.8)	5.6 (2.9)	5.9 (2.9)	5.8 (2.8)	0.5599
Mean (SD) proportion (%) of target nail involvement	73.7 (25.5)	69.9 (25.3)	69.7 (26.2)	68.5 (29.0)	70.4 (26.6)	0.4455
Mean (SD) duration (years) of current episode	11.8 (10.3)	10.5 (9.7)	10.4 (8.8)	9.9 (9.30)	10.6 (9.50)	0.4847

Table 3 Overall cure rates for toenail onychomycosis after 72 weeks according to treatment. Figures are numbers (percentage) of patients

Detail	Terbinafine 12 weeks	Terbinafine 16 weeks	Itraconazole 3 cycles	Itraconazole 4 cycles
Clinical cure	59/110 (54)	59/98 (60)	34/107 (32)	35/109 (32)
Mycological cure	81/107 (76)	80/99 (81)	41/107 (38)	53/108 (49)
Complete cure	49/107 (46)	54/98 (55)	25/107 (23)	28/108 (26)
Clinical efficacy	67/102 (66)	67/95 (71)	29/102 (28)	35/104 (34)
Global assessment:				
Patients*	86/109 (79)	78/99 (79)	47/107 (44)	57/109 (52)
Physicians†	87/110 (79)	84/99 (85)	56/107 (52)	60/109 (55)

*Patients who assessed their therapeutic results as good or very good.

†Physicians who rated patients' responses to treatment as good or very good.

clinical cure for terbinafine improved clearly and consistently until the 72 week end point, whereas for itraconazole there was no significant improvement beyond week 48. Both drugs were well tolerated, with the adverse events reported or observed within the established tolerability profile of each drug.¹⁰ The causal fungi seen in this study were the same as noted in previous studies,^{11 12} with dermatophytes accounting for the infection in 96% of the 580 participants screened for whom a fungus was cultured and, by definition, in all 496 patients randomised to treatment.

One possible explanation for the superior efficacy of terbinafine in this study is provided by the reported differences in fungistatic and fungicidal concentrations of the two drugs. Terbinafine has a primary fungicidal action against dermatophyte fungi with mean minimum inhibitory (MIC) and minimum fungicidal (MFC) concentrations of around 0.004 µg/ml, while itracona-

- Key messages**

 - Given a correct diagnosis, fungal nail disease (onychomycosis) is curable
 - Terbinafine is an allylamine antifungal with a primarily fungicidal mode of action
 - Continuous terbinafine treatment over 12 or 16 weeks achieves higher rates of clinical and mycological cure than intermittent itraconazole given over the same periods
 - Terbinafine is safe and well tolerated over 12 or 16 weeks of continuous treatment
 - Continuous terbinafine should be the current treatment of choice for onychomycosis

zole is primarily fungistatic, with mean MFC of about 0.6 µg/ml in dermatophytes.¹³ Terbinafine concentrations found in the nail are thus around 100-fold higher than the MFC of the drug,¹⁴ while the reported concentrations of itraconazole are on the borderline between fungistatic and fungicidal action.¹⁵ If fungicidal action is indeed important for effective clearing of onychomycosis variation in itraconazole concentrations in different patients might influence the therapeutic outcome, while in the case of terbinafine elimination of the pathogen would be achieved despite a wide range of variation. This therapeutic advantage is probably more evident in this study as the participants generally had severe onychomycosis, reflected by a relatively high percentage involvement of the target toenail (mean 70.4%), longstanding disease (mean 10.6 years), and, on average, onychomycosis in five other toenails.

The principal investigators of the LION study were J P Steinsson, B Sigurgeirsson, J H Olafsson (Iceland); R Suhonen, T Rantanen, S Stubb, H Heikkilä (Finland); K Gründer, J Ring, M Goos, E G Jung, E Haneke, G Niedergesäss, E Schöpf, P Altmeyer, T Ruzicka, D Reinelt (Germany); R E Boelen, L Hamminga, H J van der Rhee, T M Starink, D J Tazelaar, B J Vermeer, J Wuite, D de Hoop, L P Montmor (Netherlands); P Biggio, E di Fonzo (Italy); M J D Goodfield, D T Roberts, J Berth-Jones, D Haworth, I U Haque, C Langdon, V Mittal, R Williams, R Cranfield, R Baldwin (United Kingdom).

We thank Dr Steve Billstein, Novartis Pharmaceuticals Corporation, United States, for his constant help and guidance throughout this project, and Farid Kianifard and Angela Verzilli of Novartis; ICON Clinical Research, Dublin (Ireland), who administered the study and produced the final study report; and the staff of the PHLS Mycology Reference Laboratory, Leeds, who undertook the mycological investigations.

Contributors: EGVE assisted with the planning of the study, was responsible for all the mycological investigations, helped with the interpretation of the results, and was principally responsible for writing and revising the paper. BS was the principal study investigator and as such assisted with the planning of the study and was responsible for the final content of the protocol. BS also made a major contribution to the clinical work of the study, helped with the interpretation of the results, and assisted with writing and revising the paper. Both authors are guarantors.

Funding: Novartis Pharmaceuticals Corporation.

Conflict of interest: EGVE has received funds for research and attending symposia and also fees for speaking and consulting from a number of pharmaceutical companies, including Novartis Pharma and Janssen Pharmaceuticals. BS has received funds for research and fees for speaking and organising educational meetings from several pharmaceutical companies, including Novartis Pharma. Novartis manufactures Lamisil (terbinafine).

Fig 2 Rates (%) of mycological cure, clinical cure, and complete cure. All comparisons $P < 0.0001$ except for clinical cure $T_{12} \text{ v } I_3$ $P < 0.0015$, $T_{12} \text{ v } I_4$ $P = 0.0022$; and for complete cure $T_{12} \text{ v } I_3$ $P = 0.0007$, and $T_{12} \text{ v } I_4$ $P = 0.0044$

- 1 Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. *Br J Dermatol* 1992;126(suppl 39):23-7.
- 2 Sais G, Juggla A, Peyri J. Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study. *Br J Dermatol* 1995;132:758-61.
- 3 Editorial. Prevalence, morbidity and cost of dermatological diseases. *J Invest Dermatol* 1979;73:395-401.
- 4 Heikkilä H, Stubbs S. The prevalence of onychomycosis in Finland. *Br J Dermatol* 1995;133:699-703.
- 5 de Backer M, de Keyser P, de Vroey C, Lesaffre E. A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250 mg/day vs itraconazole 200 mg/day—a double blind comparative trial. *Br J Dermatol* 1996;134(suppl 136):16-7.
- 6 Bräutigam M, Nolting S, Schopf RE, Weidinger G for the Seventh Lamisil German Onychomycosis Study Group. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. *BMJ* 1995;311:919-21.
- 7 Gupta AK, Scher RK. Oral antifungal agents for onychomycosis. *Lancet* 1998;351:541-2.
- 8 André J, De Doncker P, Ginter G, Wang R, Stoffels P, Heremans A, et al. Intermittent pulse therapy with itraconazole in onychomycosis: an update [abstract]. 54th Annual Meeting, American Academy of Dermatology, Washington DC, 10-15 February 1996.
- 9 Tosti A, Piraccini BM, Stinchi C. Treatment of dermatophyte nail infections: an open randomised study comparing intermittent terbinafine therapy with continuous terbinafine therapy and itraconazole therapy. *J Am Acad Dermatol* 1996;34:595-600.
- 10 Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. *J Am Acad Dermatol* 1994;30:911-33.
- 11 Elewski BE. Large-scale epidemiological study of the causal agents of onychomycosis: mycological findings from the multicenter onychomycosis study of terbinafine. *Arch Dermatol* 1997;133:1317-8.
- 12 Ellis DH, Marley JE, Watson AB, Williams TG. Significance of non-dermatophyte moulds and yeasts in onychomycosis. *Br J Dermatol* 1997;134(suppl 1):40-2.
- 13 Clayton YM. Relevance of broad-spectrum and fungicidal activity of antifungals in the treatment of dermatomycoses. *Br J Dermatol* 1994;30(suppl 43):7-8.
- 14 Schatz F, Bräutigam M, Dobrowolski E, Effendy I, Haberl H, Mensing H, et al. Nail incorporation kinetics of terbinafine in onychomycosis patients. *Clin Exp Dermatol* 1995;20:377-83.
- 15 De Doncker P, Decroix J, Piérard GE, Roelant D, Woestenborghs R, Jacqmin P, et al. Antifungal pulse therapy for onychomycosis: a pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. *Arch Dermatol* 1996;132:34-41. (Accepted 10 February 1999)

Relation of *Chlamydia pneumoniae* serology to mortality and incidence of ischaemic heart disease over 13 years in the Caerphilly prospective heart disease study

David P Strachan, David Carrington, Michael A Mendall, Lydia Ballam, Julia Morris, Barbara K Butland, Peter M Sweetnam, Peter C Elwood

Abstract

Objectives To investigate the effect of *Chlamydia pneumoniae* infection on future development of ischaemic heart disease and mortality.

Design Prospective longitudinal study.

Setting Caerphilly, South Wales.

Subjects Plasma specimens were collected during 1979-83 from 1773 men aged 45-59 years. These were tested for IgG and IgA antibodies to *C pneumoniae* (TW183) by microimmunofluorescence.

Outcome measures 13 year mortality and incident ischaemic heart disease events were ascertained from death certificates, hospital records, and electrocardiographic changes at follow up every 4 to 5 years.

Results 642 men (36.2%) had IgG antibodies at a titre of ≥ 1 in 16, of whom 362 (20.4% of all men) also had detectable IgA antibodies. The prevalence of ischaemic heart disease (a history of past or current disease) at entry was similar at all IgG antibody titres but was positively related to IgA antibody titre. IgA antibody titre was positively correlated with plasma viscosity but not with other cardiovascular risk factors. Incidence of ischaemic heart disease was not associated with either IgG antibody titre or IgA antibody titre, but there were stronger and significant relations of IgA antibodies with all cause mortality and fatal ischaemic heart disease, which persisted after adjustment for conventional cardiovascular risk factors. The odds ratios associated with detectable IgA antibodies were 1.07 (95% confidence interval 0.75 to 1.53) for all incident ischaemic heart disease, 1.83 (1.17 to 2.85) for fatal ischaemic heart disease, and 1.50 (1.10 to 2.04) for all cause mortality.

Conclusion This is the first prospective demonstration of an association between IgA antibodies to *C pneumoniae*, a putative marker of chronic infection, and subsequent risk of death from ischaemic heart disease. In contrast to earlier case-control studies, IgG antibodies were not associated with either prevalent or incident ischaemic heart disease.

Introduction

Since the first report of increased concentrations of IgG and IgA antibodies to *Chlamydia pneumoniae* in patients with acute myocardial infarction or chronic coronary heart disease,¹ evidence has accumulated of an association between serological markers of this infection and clinically significant atheroma or manifestations of ischaemic heart disease.² The detection, both by polymerase chain reaction or immunocytochemistry³ and by culture,⁴ of *C pneumoniae* in atheromatous plaques lends biological plausibility to a causal link. Although there seems to be preferential localisation of this organism in cardiovascular tissue,⁵ its role in the pathogenesis of atheroma and clinical ischaemic heart disease remains controversial.²⁻⁶ In addition to possible local effects, it has been suggested that persistent *C pneumoniae* infection may result in altered lipid metabolism, increased fibrinogen concentrations, and low grade systemic inflammation, as shown by increased C reactive protein concentrations.⁷⁻¹⁰

Most published epidemiological studies have been of cross sectional or case-control design,² in which a spurious association could arise from antigenic cross reactivity between *C pneumoniae* and damaged cardiac

Department of Public Health Sciences, St George's Hospital Medical School, London SW17 0RE

David Strachan, professor
Barbara Butland, lecturer

Department of Medical Microbiology, St George's Hospital Medical School

David Carrington, senior lecturer

Division of Gastroenterology, Endocrinology and Metabolism, St George's Hospital Medical School

Michael Mendall, senior lecturer

Lydia Ballam, research assistant

Julia Morris, research assistant

continued over

BMJ 1999;318:1035-40